MAP2K1 and melanoma: While prior in vitro and clinical studies have correlated MAP2K1 missense mutations with resistance to targeted inhibitors in the context of BRAF-mutated melanomas [10, 32, 35–41], targeted therapy for melanoma with MAP2K1 in-frame deletion has not been reported to our knowledge.